Form 4: Elicio Therapeutics Director Exercises Warrants, Acquires 50,000 Shares

Director Jay Venkatesan exercised pre-funded warrants to acquire 50,000 shares of Elicio Therapeutics common stock at a price of $0.01 per share.

Summary

• Jay Venkatesan, a director at Elicio Therapeutics, exercised pre-funded warrants on November 26, 2024, to purchase 50,000 shares of the company's common stock.
• The exercise price for these warrants was $0.01 per share.
• Following this transaction, Venkatesan directly owns 179,581 shares of Elicio Therapeutics common stock.
• Venkatesan also has indirect beneficial ownership of 953 shares held by a trust, where a family member is the beneficiary.
• Venkatesan disclaims beneficial ownership of the trust's shares except for his pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing detailing a director's stock transaction. It is neither particularly positive nor negative, but the exercise of warrants could be seen as a sign of confidence.

Positives

• The exercise of warrants by a director could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders when they make transactions in their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The transaction is typical for directors exercising stock options or warrants.
• The low exercise price of $0.01 per share is common for pre-funded warrants.

Stakeholder Impact

• The transaction increases the director's stake in the company, which could be viewed positively by shareholders.

Key Dates

Keywords

Elicio Therapeutics, Jay Venkatesan, warrants, stock, insider trading, beneficial ownership, SEC Form 4